Den Europæiske Union - dansk - EMA (European Medicines Agency)

bristol myers squibb pharma eeig - fedratinib dihydrochloride monohydrate - myeloproliferative disorders; primary myelofibrosis - antineoplastiske midler - inrebic is indicated for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis, post polycythaemia vera myelofibrosis or post essential thrombocythaemia myelofibrosis who are janus associated kinase (jak) inhibitor naïve or have been treated with ruxolitinib.

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - bicalutamid - filmovertrukne tabletter - 150 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

stada arzneimittel ag - imatinibmesilat - filmovertrukne tabletter - 600 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

medice arzneimittel pütter gmbh & co. kg - melatonin - tabletter - 0,5 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - engrottehale (græspollenallergen) - frysetørret sublingual tablet - 75.000 sq.t

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - lanthanumcarbonathydrat - tyggetabletter - 1000 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orion corporation - melatonin - tabletter - 3 mg

Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

orion corporation - melatonin - tabletter - 3 mg

Den Europæiske Union - dansk - EMA (European Medicines Agency)

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - oftalmologiske - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Den Europæiske Union - dansk - EMA (European Medicines Agency)

roche registration gmbh - faricimab - wet macular degeneration; macular edema; diabetes complications - oftalmologiske - vabysmo is indicated for the treatment of adult patients with:neovascular (wet) age-related macular degeneration (namd),visual impairment due to diabetic macular oedema (dme).